3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
19
Triple Negative Breast Neoplasms
15
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
4
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
3
Brain Neoplasms
3
Salivary Gland Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Urothelial Cancer
1
Laryngeal Neoplasms
1
Klatskin Tumor
1
Hypopharyngeal Neoplasms
1
HER2-negative Breast Cancer
1
Glioblastoma
1
Interventions
Sorafenib
10
Magnetic Resonance Spectroscopy
10
trametinib
8
lenvatinib
8
dabrafenib
7
pembrolizumab
6
Nivolumab
6
Iodine-131
6
Everolimus
6
Sunitinib
5
Paclitaxel
5
vandetanib
4
apatinib
4
Thyrotropin Alfa
4
Doxorubicin
4
selpercatinib
3
anlotinib
3
Specimen Handling
3
Radiotherapy
3
Ipilimumab
3
Iodine-124
3
Fluorodeoxyglucose F18
3
Cisplatin
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tislelizumab
2
tipifarnib
2
surufatinib
2
spartalizumab
2
pazopanib
2
omipalisib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thyroid Neoplasms
×
sacituzumab govitecan
×
Clear all
NCT06923826
2025-07-25
TROP2
National University Hospital, Singapore
Phase 2
Recruiting
32 enrolled